It is important to note that the administration of cancer drugs, including chemotherapy, biological and immunotherapy is a complex process fraught with the potential for patient harm. Many cancer drugs have serious side effects and risks to patient safety grow as the number of multi-drug regimens expands and oral chemotherapy becomes commonplace. Under the NCCP, clinicians with appropriate expertise and skills, in conjunction with colleagues in multidisciplinary teams, have access to effective medicinal products necessary for the treatment of cancer in line with international best practice. There is no need for legislation to improve access. The enactment of a Bill which would allow medical practitioners to single-handedly prescribe these complex drugs without the benefit of multidisciplinary assessment and support and, in the longer term, the implementation of national treatment policies and guidelines would be wrong.